Screener
ADMA Biologics ADMA Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accounts payable | 8,846 | 9,409 |
| Accrued expenses | (1,478) | (5,206) |
| Other current and non-current liabilities | (630) | (602) |
| Net cash provided by operating activities | 87,788 | 1,464 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchase of property and equipment | (4,799) | (7,123) |
| Acquisition of intangible assets | (53) | (124) |
| Proceeds on the sales of assets held for sale | 5,000 | - |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's operating cash flow?
- ADMA Biologics (ADMA) reported operating cash flow of $29.54M in Q2 2026.
- How has ADMA Biologics's operating cash flow changed year-over-year?
- ADMA Biologics's operating cash flow increased by 39.7% year-over-year, from $21.14M to $29.54M.
- What is the long-term trend for ADMA Biologics's operating cash flow?
- Over 4 years (2021 to 2025), ADMA Biologics's operating cash flow has grown at a -18.2% compound annual growth rate (CAGR), from -$112.37M to $50.4M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about ADMA Biologics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude